Cipla profit drops 39.18% YoY despite operating margin rebound
The consolidated margin recovered sharply QoQ, but higher depreciation, interest and weaker other income pulled pre-tax profit down 38.87% YoY.
Filed 23 Jul 2026, 12:00 IST · Cipla Ltd (CIPLA)
Key takeaways
- Consolidated net profit fell 39.18% YoY as expenses grew 4.02% against 2.33% revenue growth, while depreciation rose 20.39%.
- Operating margin rebounded 8.89 percentage points QoQ to 30.88% as revenue rose 8.84% and expenses declined 3.56%.
- Other income contributed 19.49% of pre-tax profit, making the Rs 785.55 cr profit less dependent on operating earnings than the headline margin suggests.
Price around the results
Revenue growth failed to cover the cost increase
Cipla's consolidated revenue grew only 2.33% YoY, while expenses rose 4.02%, leaving operating profit down 1.28%. The sharper decline came below operating profit: depreciation increased 20.39%, interest rose 21.21%, and other income fell 18.43%, driving pre-tax profit down 38.87%. The tax rate was almost unchanged YoY at a 0.25 percentage-point increase, so the 39.18% fall in net profit was not mainly a tax-rate effect.
Margin recovery was driven by lower sequential expenses
The QoQ recovery was materially better: revenue increased 8.84% while expenses declined 3.56%, expanding operating margin by 8.89 percentage points. This lifted margin to 30.88%, although it remained 1.13 percentage points below Q1FY26 because costs grew faster than revenue on a YoY basis. Cipla's margin was 6.24 percentage points above the 24.64% median for the eight Healthcare peers that had reported the quarter.
Margin rebounded after two quarters of decline
Operating margin had fallen from 33.83% in Q2FY26 to 30.35% in Q3FY26 and 21.99% in Q4FY26 before recovering to 30.88% in Q1FY27. The sequential profit improvement was therefore an operating rebound, but higher interest of 29.70% and a 5.05 percentage-point increase in the tax rate limited the conversion into net profit. Other income accounted for 19.49% of pre-tax profit, which is a material contribution to reported earnings quality.
gVentolin launch gives management a near-term execution marker
Management said Cipla launched gVentolin in the US during the quarter and completed initial shipments. The company also said it plans to ramp up gVentolin supply over the coming quarters, making shipment scale a specific business development to track alongside the margin recovery.
The initial stock decline was within Cipla's usual results range
The stock fell 1.56% on the results date, with volume at 3.19 times its usual level. That move was less severe than Cipla's 2.73% median absolute move after its past eight results, while the historical direction has been negative in five of those eight instances.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹7,119 cr | ₹6,541 cr | +8.84% | +2.33% |
| Other income | ₹211 cr | ₹148 cr | +42.35% | -18.43% |
| Expenses | ₹4,921 cr | ₹5,103 cr | -3.56% | +4.02% |
| Operating profit | ₹2,198 cr | ₹1,439 cr | +52.81% | -1.28% |
| Operating margin (%) | 30.88% | 21.99% | — | — |
| Interest | ₹17 cr | ₹13 cr | +29.70% | +21.21% |
| Depreciation | ₹304 cr | ₹383 cr | -20.55% | +20.39% |
| Profit before tax | ₹1,082 cr | ₹707 cr | +53.02% | -38.87% |
| Tax | ₹295 cr | ₹157 cr | +87.85% | -38.30% |
| Net profit | ₹786 cr | ₹543 cr | +44.80% | -39.18% |
| EPS (₹) | ₹9.77 | ₹6.87 | +42.21% | -39.20% |
Operating margin of 30.88% compares with a Healthcare sector median of 24.64% across 8 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -1.56% | -1.03% |
| Next session | -0.43% | — |
Volume on the results session was 3.19× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Cipla executed initial US shipments of gVentolin during Q1 FY27.
Guidance & outlook
- Cipla plans to ramp up gVentolin supply over the coming quarters.
- Cipla targets an 80% renewable electricity share for India manufacturing by FY2029-30.
- Cipla targets water neutrality for India manufacturing.
- Cipla plans to maintain zero-waste-to-landfill status in India and expand coverage to overseas sites.
New products
- Cipla launched gVentolin in the US during the quarter, with initial shipments executed.
What to watch
- Whether operating margin holds above the 30.88% Q1FY27 level after the 8.89-percentage-point QoQ recovery.
- Whether expenses remain below revenue growth after rising 4.02% YoY against 2.33% revenue growth.
- Whether other income stays near its 19.49% share of pre-tax profit as operating earnings carry more of the result.